Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)

ClinicalTrials.gov ID: NCT02186821

Public ClinicalTrials.gov record NCT02186821. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1

Study identification

NCT ID
NCT02186821
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
47 participants

Conditions and interventions

Interventions

  • Ceritinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 16, 2014
Primary completion
Dec 12, 2017
Completion
Dec 12, 2017
Last update posted
Apr 7, 2021

2014 – 2017

United States locations

U.S. sites
21
U.S. states
18
U.S. cities
20
Facility City State ZIP Site status
St Joseph Heritage Healthcare St. Joseph Heritage Santa Rosa California 94503
Sarah Cannon Research Institute Denver Colorado 80218
Rocky Mountain Cancer Centers Dept of Rocky Mountain (2) Greenwood Village Colorado
Florida Cancer Specialists Florida Cancer Specialists (31 Fort Myers Florida 33901
Northwestern University Northwestern (6) Chicago Illinois 60611
Physicians Clinic of Iowa Cedar Rapids Iowa 52403
Holy Cross Hospital Holy Cross (2) Silver Spring Maryland 20910
Southeast Nebraska Oncology Lincoln Nebraska 68510
Comprehensive Cancer Centers of Nevada CCC of Nevada (1) Las Vegas Nevada 89109
Duke University Medical Center Seeley G. Mudd Bldg. Durham North Carolina 27710
Wake Forest Baptist Health Health Sciences Winston-Salem North Carolina 27157
Sanford Hematology Oncology Fargo North Dakota 58122
Columbus Hematology and Oncology PA Columbus Hem and Onc (2) Columbus Ohio 39705
Andrew and Patel Associates Camp Hill Pennsylvania 17011
Rhode Island Hospital Rhode Island Hosp. (2) Providence Rhode Island 02903
Sanford University of South Dakota Medical Center Sanford Clinical Research Sioux Falls South Dakota 57104
Oncology Consultants Oncology Group Houston Texas 77024
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3) Houston Texas 77030
Utah Cancer Specialists Utah Cancer Specialists Salt Lake City Utah 84106
Swedish Cancer Institute Swedish Cancer Institute Seattle Washington 98104
Aurora Research Institute Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02186821, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 7, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02186821 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →